Evidence map›Paper›PMID 40470411›Full record

ArticleCureus2025

Resuscitating Through the Smoke: Novel Use of Cyanocobalamin in a Pediatric House Fire Victim.

David R Janese, Michael Donald, Emily McGee, Jacquelyn Bowers

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

David R JaneseEmergency Medicine/Family Medicine, Louisiana State University Health Shreveport (LSUHS), Shreveport, USA.
Michael DonaldEmergency Medicine/Family Medicine, Louisiana State University Health Shreveport (LSUHS), Shreveport, USA.
Emily McGeePharmacology, Louisiana State University Health Shreveport (LSUHS), Shreveport, USA.
Jacquelyn BowersEmergency Medicine, Louisiana State University Health Shreveport (LSUHS), Shreveport, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydroxocobalamin (Cyanokit® (HealthTech BioActives, Spain)) is the first-line antidote for suspected cyanide toxicity, typically infused intravenously over 10-15 minutes. However, in critically unstable patients, faster delivery may be essential. This case describes a seven-year-old female patient found pulseless after exposure to heavy smoke in a residential fire. Following return of spontaneous circulation (ROSC) in the emergency department, the patient remained severely acidotic and hypoxic despite confirmation of a secure airway and initiation of mechanical ventilation. A 5 g dose of hydroxocobalamin was administered as a rapid push over two minutes. The intervention was well tolerated and associated with a significant 13.8% decrease in carboxyhemoglobin levels within 20 minutes, alongside progressive improvement in metabolic parameters. Although the patient ultimately suffered irreversible hypoxic-ischemic brain injury, this case highlights the potential utility of push-dose hydroxocobalamin in time-critical resuscitation scenarios involving suspected cyanide toxicity.

Indexed as

carbon monoxide (co) poisoningcyanide poisoninghydroxocobalaminpediatric resuscitationpush-dose medication administrationsmoke inhalation injury

Identifiers

PMID40470411
PMCPMC12135720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.